Humacyte Inc. (HUMA)
HUMA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/0001818382-26-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HUMA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001818382 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | -$40.8M |
| Operating income | -$108.1M |
| Net margin | -2003.6% |
| Operating margin | -5306.0% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $50.5M |
| Total assets | $116.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 73.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-10 |
| Cash and burn | $64.5M cash; operating cash flow -$22.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 277,798,105 (2026-11-10); 187,271,321 a year earlier; 103,575,256 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-06-11 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-07-31 |
| Delisting | 25-NSE filed | 25-NSE 2026-08-25 |
| Auditor | PricewaterhouseCoopers LLP, Raleigh, North Carolina, United States | PCAOB Form AP 2026-04-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $90K, sold $41K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.0M | -$15.5M | -$15.0M | $64.5M | $36.8M | $2.4M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $406K | -$36.8M | -$22.1M | $79.9M | $36.3M | $2.1M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $495K | -$17.6M | -$25.1M | $48.5M | $35.9M | $2.0M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $467K | -$24.8M | -$26.1M | $50.5M | $35.4M | $2.0M | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | $753K | -$17.5M | -$23.9M | $19.5M | No debt tags | $1.6M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $301K | -$37.7M | -$26.4M | $38.0M | No debt tags | $818K | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $517K | $39.1M | -$28.6M | $62.8M | No debt tags | $517K | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $0 | -$20.9M | -$26.6M | $44.9M | $0 | $0 | 10-K 2026-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-11 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 506 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +24.6% |
| 1 month | +55.4% |
| 3 months | +1.5% |
| Year to date | -41.9% |
| 1 year | -53.1% |
| From 52-week high | -62.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TARA | Protara Therapeutics Inc. | $2.38 | -5.93% | $146.5M |
| STRO | Sutro Biopharma Inc. | $9.32 | -5.09% | $154.7M |
| IPHA | Innate Pharma S.A. ADS | $1.41 | -1.06% | $156.9M |
| IVVD | Invivyd Inc. | $0.5377 | -7.63% | $158.5M |
| FATE | Fate Therapeutics Inc. | $1.14 | -10.94% | $138.6M |
| ENGN | enGene Therapeutics Inc. | $1.89 | -21.58% | $126.7M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $0.9798 | -2.02% | $125.1M |
| PALI | Palisade Bio Inc. | $1.03 | -8.04% | $184.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier